Chiara Biosciences

Chiara Biosciences is a biotechnology company focused on developing novel therapeutic approaches for neurodegenerative diseases and oncology by targeting tunneling nanotubes (TNTs). Founded as a spin-off from the Institut Pasteur by Dr. Chiara Zurzolo, the company leverages her pioneering research into how TNTs facilitate the intercellular spread of pathogenic proteins like alpha-synuclein and tau. By inhibiting the formation or function of these nanotubes, Chiara Biosciences aims to halt the progression of diseases such as Parkinson's and Alzheimer's. In oncology, the company explores the role of TNTs in tumor growth and drug resistance, particularly in aggressive cancers like glioblastoma. The company's platform represents a first-in-class approach to addressing protein misfolding and cellular communication in complex diseases.